Clinical Trial

Steroids Combined With Ruxolitinib as First-Line Therapy for Grade II Acute Graft-versus-Host Disease

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the efficacy and safety of low-dose corticosteroids combined with ruxolitinib in the treatment of grade II acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-04.
Trial Details
NCT Number NCT07576010
Lead Sponsor Daihong Liu
Conditions Acute Graft-versus-host Disease
Enrollment 30 participants
Start Date 2025-01-17
Primary Completion 2027-12-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-15